Off-Label Drug Proves Its Mettle in Relapsing Multiple Sclerosis

[ad_1]

(MedPage Today) — Off-label rituximab was noninferior to ocrelizumab (Ocrevus) in people with newly diagnosed relapsing multiple sclerosis (MS) and recent disease activity, the phase III OVERLORD-MS trial showed.
At 2 years, the estimated probability…

[ad_2]

Source link : https://www.medpagetoday.com/neurology/multiplesclerosis/122021

Author :

Publish date : 2026-07-01 21:26:00

Copyright for syndicated content belongs to the linked Source.